OmniComm Systems, Inc. (OTC: OMCM.OB), a global provider of eClinical solutions announced that it released TrialOne, a fully integrated, MS .NET, web‐based solution designed to automate the Phase I Clinical Trial Process. TrialOne provides web‐based tools used to recruit study volunteers, schedule screening appointments, collect screening data, directly capture real‐time data, track sample transfers and address the unique requirements of early phase studies. Within each study, real‐time electronic data is captured and validated at the subject’s bedside or at a subject queuing station. Enhanced workflow technology automates sample processing throughout the lab. TrialOne supports a myriad of directly attached biomedical monitoring devices such as the GE Healthcare DINAMAP® family of vital signs monitors and various ECG devices.
TrialOne enables Phase I Clinics to share data with other stakeholders via the internet and provides a flexible ad‐hoc reporting tool to help export and report data in various formats including Adobe® PDF, Microsoft® Excel and Word. Further extensibility of the TrialOne suite via integration to our flagship EDC product, TrialMaster®, using OmniConnect™, our enhanced web services API, and an integrated pharmacy module is planned for release later this year.
“TrialOne is the only available product that handles all aspects of the Phase I process from subject recruitment and clinical wokflow management to laboratory sample management,” said OmniComm’s CTO, Randy Smith.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.